Date: 2016-10-10
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the World Vaccine Congress
Company: Allergy Therapeutics (UK)
Product: microcrystalline tyrosine (MCT)
Action
mechanism: adjuvant
Disease:
Therapeutic area: Technology - Services
Country:
Trial details:
Latest
news: * On October 10, 2016, Allergy Therapeutics, together with its wholly-owned division, Bencard Adjuvant Systems (BAS), which specialises in developing and optimising adjuvants for prophylactic vaccination and allergen immunotherapy, announced new data using a novel adjuvant system that shows enhancement of efficacy in a malaria vaccine model. These results have been presented at the World Vaccine Congress in Barcelona, Spain.
In an oral session entitled: "Platform technologies to emerging pathogens", Allergy Therapeutics' principal scientist, Dr Matthew Heath, PhD, in conjunction with the Jenner Institute, University of Oxford, presented new information on adjuvant activity and enhanced efficacy in a candidate vaccine formulation against Plasmodium vivax (malaria). Microcrystalline tyrosine (MCT), the aluminium-free depot adjuvant used in Allergy Therapeutics' successfully marketed and rapidly growing Pollinex Quattro® immunotherapy product, was shown to elicit high, sustained antibody titres in a preclinical model and demonstrated increased protective efficacy compared to existing adjuvants.
MCT has also synergistic effects when coupled with Virus Like Particles (VLP) to create a combined and unique Adjuvant System, AdSys-VcT. The data indicated a significant increase in specific antibodies and other immune parameters indicative of protective efficacy compared to aluminium salts. The potential for this novel adjuvant system in infectious disease applications was concluded to be highly significant.
Allergy Therapeutics has been pioneering the development of novel adjuvant systems with the combination of MCT and monophosphoryl lipid A (MPL) in allergy immunotherapy, allowing for the successful introduction of the concept of ultra-short course immunotherapy in the allergy vaccines market.
